Back

Finerenone versus spironolactone in HFpEF patients with type 2 diabetes and CKD: a real-world comparative analysis

30 August 2026 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Exploring the peripheries in HFpEF Heart Failure with Preserved Ejection Fraction (HFpEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Thomas Elimihele

University of Iowa Hospitals and Clinics, Iowa City (United States of America)

6 More presentations in this session

Presentation thumbnail
Non-invasive pulse-wave-analysis for screening of HFpEF in at-risk patients: findings from the ARTS-PREDICTION study
Doctor J. Gronwald (Goettingen, DE)
Abstract Slides Video
Presentation thumbnail
Incremental risk stratification using the H2FPEF score in patients with chronic kidney disease and unexplained dyspnea
Mr A. Al-Rubai (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Prevalence and reclassification of monoclonal gammopathy in elderly HFpEF patients undergoing ATTR-CM screening: A PATCH-HFpEF sub-study
Doctor P. Liao (TW)
Abstract Slides Video
Presentation thumbnail
Diagnostic performance of the H₂FPEF score and cardiovascular burden in patients with chronic kidney disease: a cross-sectional study
Doctor M. Covic (Iasi, RO)
Abstract Slides Video
Presentation thumbnail
Indoxyl sulfate (IS)-CTSK axis mediates cardiac fibroblast activation in CKD-Related HFpEF
Doctor Y. Zou (Shanghai, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Exploring the peripheries in HFpEF

The Event

Event poster

ESC Congress 2026

30 August 2026 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Comparative effectiveness of finerenone versus spironolactone in patients hospitalized with heart failure: a prospective cohort study
31 August 2026
thumbnail
Congress Presentation
Finerenone in patients with heart failure and diabetic kidney disease: comparison of mineralocorticoid receptor antagonists. FINARM study
1 September 2025
thumbnail
Congress Presentation
Renal function and hyperkalemia with first-line eplerenone in obese patients with hypertension: randomized safety data from the HEBRO trial
30 August 2026
thumbnail
Congress Presentation
Efficacy and safety of finerenone in patients with chronic kidney disease and cardiovascular diseases: An individual participant data pooled analysis (INFINITY)
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources